Marc A. Began, Executive Vice President and General Counsel of Axogen, Inc. (NASDAQ:AXGN), filed a Form 4 on August 12, 2026, disclosing the exercise of 67,500 stock options and the same-day sale of 67,500 shares of common stock on August 10, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Began exercised 67,500 employee stock options at a conversion price of $8.16 per share on August 10, 2026.
  • Share sale: 67,500 shares of common stock were sold at a weighted average price of $47.345 per share, with individual transactions ranging from $47.16 to $47.72 per share.
  • 10b5-1 plan: The sales were executed under a Rule 10b5-1 trading plan adopted by Began on March 11, 2026.
  • Remaining ownership: Following the transactions, Began directly held 50,135 shares of Axogen common stock, with 22,500 stock options remaining.
  • Vesting schedule: The underlying option grant vests fully on March 1, 2027, with 50% having vested on March 1, 2025, and an additional 12.5% vesting each six months thereafter.

Axogen General Counsel's Option Exercise and Same-Day Sale Details

According to the filing, Marc A. Began, serving as EVP and General Counsel of Axogen, Inc., conducted two linked transactions on August 10, 2026. He first exercised 67,500 employee stock options at an exercise price of $8.16 per share, bringing his directly held common stock to 117,635 shares following that step.

Began then disposed of 67,500 shares of common stock in an open-market sale at a weighted average price of $47.345 per share. The filing notes that these shares were sold across multiple transactions at prices ranging from $47.16 to $47.72 per share, and that full per-transaction detail is available upon request to the issuer, any security holder, or SEC staff. After this disposal, his direct beneficial ownership stood at 50,135 shares of common stock.

The filing also discloses that 22,500 employee stock options remain outstanding with an exercise price of $8.16 and an expiration date of March 1, 2033. The filing indicates all shares underlying the original option grant will be fully vested on March 1, 2027, based on a schedule where 50% vested on March 1, 2025, and an additional 12.5% vest every six months after that date. The filing confirms the sales were made pursuant to a Rule 10b5-1 trading plan Began adopted on March 11, 2026, and the filing itself is marked to indicate the transaction was made pursuant to such a plan.

What Was Disclosed

Axogen EVP and General Counsel Marc A. Began disclosed the exercise of 67,500 stock options and the sale of 67,500 common shares on August 10, 2026, under a pre-established 10b5-1 plan, leaving him with 50,135 shares and 22,500 remaining options.